门冬氨酸钾镁治疗急性心肌梗死的临床观察  

The clinical observation of potassium-magnesium aspartate in the treatment of acute myocardial infarction

作　　者：杨屹云[1] 李宪伦[1] 钱端[1] 王云[1] 秦延莉[1] 柯元南[1] 

机构地区：[1]中日友好医院心内科,北京100029

出　　处：《中华老年心脑血管病杂志》2001年第4期233-235,共3页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

摘　　要：目的　观察门冬氨酸钾镁在治疗急性心肌梗死中的作用。方法　采用随机 ,单盲 ,对照的方法将 118例急性心机梗死患者分为门冬氨酸钾镁治疗组和对照组 ,观察急性心肌梗死发生后 1个月内 ,两组中心律失常、心力衰竭的发生率和死亡率。结果　治疗组与对照组恶性心律失常发生率分别为 8.9%和 2 2 .6 % (P <0 .0 5 ) ;心力衰竭发生率分别为 10 .7%和 2 5 .8% (P<0 .0 5 ) ;1个月内两组死亡率分别为 5 .4%和 17.7% (P<0 .0 5 ) 。Objective To observe the benefit of potassium-magnesium aspartate in treatment of acute myocardial infarction (AMI).Methods One hundred and eighteen AMI patients were randomly assigned to receive intravenous potassium-magnesium aspartate (magnesium group,n=56) or controls (placebo group,n=62) in a single-blind controlled study for examining the effects of potassium-magnesium aspartate treatment on the incidence of arrhythmia and heart failure,and the fatality rate in hospital.Results The morbidity of arrhythmia in magnesium and placebo groups was 8.9% and 22.6%(P<0.05),respectively;the incidence of heart failure in the two groups was 10.7% and 25.8%(P<0.05),respectively;and the the mortality in the two groups was 5.4% and 17.7%(P<0.05),respectively.Conclusion Potassium-magnesium aspartate is a safe and useful therapy in reducing the incidence of arrhythmia and heart failure,and the fatality rate after acute myocardial infarction.

关 键 词：门冬氨酸钾镁 急性心肌梗塞 心律失常 心力衰竭 死亡率 

分 类 号：R542.22[医药卫生—心血管疾病]